Healthcare professionals prescribing biosimilars should understand the scientific data needed to attain regulatory approval when consulting patients on treatments. This consultation ensures patients understand which medicine will be administered and may help empower the patient with the knowledge they need to feel confident in the safety, efficacy and quality of the biosimilar while giving them a potentially lower cost treatment option.